Arilsulfonamida compounds as modulators of host cck1 / cck2

摘要

Refers to arilsulfonamida thereof of formula (i), in which X is alkyl (c1-c2) or a Link; r1 is phenyl, naphthyl, 6,7,8,9 - tetrahydro - 5H - benzociclohepten thiocyanatoacetate 5,6,7,8 and 9 optionally substituted OXO, piridilo, pirazinilo, furanilo, tiofenilo, among others, optionally substituted with 1 to RQ 3 which is alkyl (c1-c4), o, F, CL, BR, I, CF3, among others; R2 is H, alkyl (C1 - C6)Cycloalkyl (C3 - C7), among others, ra is alkyl, cycloalkyl (C1 - C6) (C3 and C6), phenyl, furanilo, tiofenilo, pyrrole-1 - ILO, Benzyl, oalquilo (C1 - C6) (cyclohexylmethyl) amino phenyl merged, among others; RB is 2.4 or 2.6 - difluor RB or two adjacent substituents in positions 2 and 3 taken as co Njunta Heterocycles are 5 to 6 members, such as pyrazine, thiazole, thiadiazole,Among others; RC are independently h, alkyl (c1-c4) alkyl (C0, C2) COOH coo - alkyl (C0, C2) - anilloa, among others; Rd is H, alkyl, among others. Are preferred: (*) - 2 - (benzo [1,2,5] - 4 - thiadiazole sulfonylamino) - 4 - chlorine - N - (2 - (4-chloro phenyl) - propyl] - benzamide, acid (*) - 2 - (benzo [1,2,5] - 4 - thiadiazole sulfonylamino) - 4 - Iodine - benzoylamino] - 3 - (3,4 - Dichloro phenyl) - propionic acid, among others.It also relates to a Pharmaceutical composition. These compounds are dual inhibitors of Cholecystokinin receptors (cck1 / cck2) and are useful in the treatment of pancreatitis, or non Erosive gastroesophageal reflux disease